Betamethasone dipropionate and salicylic acid lotion for nonscalp dermatoses
- PMID: 6850723
Betamethasone dipropionate and salicylic acid lotion for nonscalp dermatoses
Abstract
A multicentric open study was conducted to evaluate the efficacy and safety of betamethasone dipropionate and salicylic acid lotion in 86 patients with psoriasis or other steroid-responsive dermatoses of nonscalp body areas. Medication was applied to affected areas for 14 to 31 days. Patients were evaluated weekly. Within 14 to 21 days of therapy, there were favorable results in 68/86 (79%) patients. A complete clearing or marked improvement of signs and symptoms was achieved in 78/86 (91%) patients; improvement occurred in 7/86 (8%). Treatment failed in one (1%) patient. Three transient adverse reactions were reported.
Similar articles
-
[Therapy of erythrosquamous dermatoses. Betamethasone dipropionate plus salicylic acid in comparison with betamethasone dipropionate solution].Fortschr Med. 1983 Oct 6;101(37):1679-83. Fortschr Med. 1983. PMID: 6227542 Clinical Trial. German.
-
Betamethasone dipropionate (0.05%) plus salicylic acid (3%) ointment versus dexamethasone trimethyl acetate (1%) and salicylic acid 4% ointments in chronic dermatoses.Indian J Dermatol. 1987 Apr;32(2):41-4. Indian J Dermatol. 1987. PMID: 3453353 No abstract available.
-
Calcipotriol: clinical trial versus betamethasone dipropionate + salicylic acid.Acta Derm Venereol Suppl (Stockh). 1994;186:47. Acta Derm Venereol Suppl (Stockh). 1994. PMID: 8073835 Clinical Trial. No abstract available.
-
Optimal efficacy of topical corticoids in psoriasis.Semin Dermatol. 1992 Dec;11(4):275-7. Semin Dermatol. 1992. PMID: 1493090 Review.
-
DFD-01: a novel topical formulation of betamethasone dipropionate for the treatment of extensive psoriasis.Expert Rev Clin Immunol. 2017 Feb;13(2):85-91. doi: 10.1080/1744666X.2017.1270756. Epub 2016 Dec 21. Expert Rev Clin Immunol. 2017. PMID: 27967262 Review.
MeSH terms
Substances
LinkOut - more resources
Medical